When do biologic drug patents expire and when will biosimilars launch?

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997	10,894,042	2035-11-10
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	February 19, 2002	10,894,042	2035-11-10
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	May 07, 2001	10,894,042	2035-11-10
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	November 14, 2014	10,894,042	2035-11-10
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	October 12, 2004	10,894,042	2035-11-10
Glaxosmithkline Llc	BEXXAR	tositumomab and iodine i-131 tositumomab	Injection	125011	June 27, 2003	10,894,042	2035-11-10
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019	February 19, 2002	10,894,042	2035-11-10
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Title:	Methods and pharmaceutical compositions for the treatment of cancer
Abstract:	The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. More particularly, the present invention relates to a method of treating cancer in subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R antagonist.
Inventor(s):	Couvineau Alain, Gratio Valérie, Nicole Pascal, Voisin Thierry
Assignee:
Application Number:	US15525771
Patent Claims:

Claims for Patent: 10,894,042